Published in Angew Chem Int Ed Engl on April 01, 2010
Delivery of intact transcription factor by using self-assembled supramolecular nanoparticles. Angew Chem Int Ed Engl (2011) 0.98
Curb challenges of the "Trojan Horse" approach: smart strategies in achieving effective yet safe cell-penetrating peptide-based drug delivery. Adv Drug Deliv Rev (2013) 0.97
Co-administration of protein drugs with gold nanoparticles to enable percutaneous delivery. Biomaterials (2010) 0.85
Transcutaneous antigen delivery system. BMB Rep (2013) 0.80
A Prodrug-type, MMP-2-targeting Nanoprobe for Tumor Detection and Imaging. Theranostics (2015) 0.79
In vivo delivery of cell-permeable antisense hypoxia-inducible factor 1α oligonucleotide to adipose tissue reduces adiposity in obese mice. J Control Release (2012) 0.79
Nose-to-brain delivery of macromolecules mediated by cell-penetrating peptides. Acta Pharm Sin B (2016) 0.75
CPP-Assisted Intracellular Drug Delivery, What Is Next? Int J Mol Sci (2016) 0.75
Noninvasive Transdermal Vaccination Using Hyaluronan Nanocarriers and Laser Adjuvant. Adv Funct Mater (2016) 0.75
Solid-in-oil nanodispersions for transdermal drug delivery systems. Biotechnol J (2016) 0.75
Robust vaccine formulation produced by assembling a hybrid coating of polyethyleneimine-silica. Chem Sci (2015) 0.75
Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci U S A (1994) 5.00
Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv Drug Deliv Rev (2003) 3.25
Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat Med (2000) 1.98
Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J Clin Invest (2004) 1.58
HIV TAT forms pores in membranes by inducing saddle-splay curvature: potential role of bidentate hydrogen bonding. Angew Chem Int Ed Engl (2008) 1.47
Cutaneous vaccination: the skin as an immunologically active tissue and the challenge of antigen delivery. J Control Release (2000) 1.18
Direct visualization of lipid domains in human skin stratum corneum's lipid membranes: effect of pH and temperature. Biophys J (2007) 1.11
Nontoxic membrane translocation peptide from protamine, low molecular weight protamine (LMWP), for enhanced intracellular protein delivery: in vitro and in vivo study. FASEB J (2005) 1.10
IFN-mediated induction of MHC antigen expression on human keratinocytes and its influence on in vitro alloimmune responses. J Immunol (1988) 1.06
Transcutaneous immunization induces mucosal and systemic immunity: a potent method for targeting immunity to the female reproductive tract. Mol Immunol (2000) 0.99
Lipid reorganization induced by membrane-active peptides probed using differential scanning calorimetry. Biochim Biophys Acta (2009) 0.98
Membrane-mimetic nanocarriers formed by a dipalmitoylated cell-penetrating peptide. Angew Chem Int Ed Engl (2005) 0.95
Lysis of human keratinocytes by allogeneic HLA class I-specific cytotoxic T cells. Keratinocyte ICAM-1 (CD54) and T cell LFA-1 (CD11a/CD18) mediate enhanced lysis of IFN-gamma-treated keratinocytes. J Immunol (1991) 0.95
Low molecular weight protamine as an efficient and nontoxic gene carrier: in vitro study. J Gene Med (2003) 0.94
Controlled bioactive nanostructures from self-assembly of peptide building blocks. Angew Chem Int Ed Engl (2007) 0.89
Cell-penetrating-peptide-coated nanoribbons for intracellular nanocarriers. Angew Chem Int Ed Engl (2007) 0.87
Interferon-gamma enhances cytotoxic T lymphocyte recognition of endogenous peptide in keratinocytes without lowering the requirement for surface peptide. Immunol Cell Biol (2002) 0.84
Reduced reactivity towards anti-protamine antibodies of a low molecular weight protamine analogue. Thromb Res (2001) 0.84
Design, construction, and intracellular activation of an intramolecularly self-silenced signal transduction inhibitor. Angew Chem Int Ed Engl (2005) 0.81
Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials (2007) 3.12
Cancer theranostics: the rise of targeted magnetic nanoparticles. Trends Biotechnol (2011) 1.60
Polyethyleneimine-modified iron oxide nanoparticles for brain tumor drug delivery using magnetic targeting and intra-carotid administration. Biomaterials (2010) 1.42
Polyethylene glycol modified, cross-linked starch-coated iron oxide nanoparticles for enhanced magnetic tumor targeting. Biomaterials (2010) 1.33
Glioma selectivity of magnetically targeted nanoparticles: a role of abnormal tumor hydrodynamics. J Control Release (2007) 1.29
Physiologically based pharmacokinetic model for T84.66: a monoclonal anti-CEA antibody. J Pharm Sci (2010) 1.15
Comparison of electron spin resonance spectroscopy and inductively-coupled plasma optical emission spectroscopy for biodistribution analysis of iron-oxide nanoparticles. Mol Pharm (2010) 1.12
Simvastatin maintains osteoblastic viability while promoting differentiation by partially regulating the expressions of estrogen receptors α. J Surg Res (2011) 1.11
Nontoxic membrane translocation peptide from protamine, low molecular weight protamine (LMWP), for enhanced intracellular protein delivery: in vitro and in vivo study. FASEB J (2005) 1.10
The role of STAT1/IRF-1 on synergistic ROS production and loss of mitochondrial transmembrane potential during hepatic cell death induced by LPS/d-GalN. J Mol Biol (2007) 1.10
Magnetic brain tumor targeting and biodistribution of long-circulating PEG-modified, cross-linked starch-coated iron oxide nanoparticles. Biomaterials (2011) 1.05
Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides. Biomaterials (2011) 1.04
Substantiating in vivo magnetic brain tumor targeting of cationic iron oxide nanocarriers via adsorptive surface masking. Biomaterials (2009) 1.02
Synthesis of doxorubicin-peptide conjugate with multidrug resistant tumor cell killing activity. Bioorg Med Chem Lett (2005) 1.01
Brain tumor targeting of magnetic nanoparticles for potential drug delivery: effect of administration route and magnetic field topography. J Control Release (2011) 1.01
Influence of formulation variables in transdermal drug delivery system containing zolmitriptan. Int J Pharm (2011) 0.98
Chronic ethanol consumption-induced pancreatic {beta}-cell dysfunction and apoptosis through glucokinase nitration and its down-regulation. J Biol Chem (2010) 0.98
Curb challenges of the "Trojan Horse" approach: smart strategies in achieving effective yet safe cell-penetrating peptide-based drug delivery. Adv Drug Deliv Rev (2013) 0.97
Characterization, in vitro cytotoxicity assessment, and in vivo visualization of multimodal, RITC-labeled, silica-coated magnetic nanoparticles for labeling human cord blood-derived mesenchymal stem cells. Nanomedicine (2009) 0.97
Magnetically-enabled and MR-monitored selective brain tumor protein delivery in rats via magnetic nanocarriers. Biomaterials (2011) 0.95
Low molecular weight protamine as an efficient and nontoxic gene carrier: in vitro study. J Gene Med (2003) 0.94
Insulin-cell penetrating peptide hybrids with improved intestinal absorption efficiency. Biochem Biophys Res Commun (2005) 0.93
Abl-SH3 binding protein 2, 3BP2, interacts with CIN85 and HIP-55. FEBS Lett (2007) 0.93
L-Asparaginase encapsulated intact erythrocytes for treatment of acute lymphoblastic leukemia (ALL). J Control Release (2009) 0.93
Gum arabic-coated magnetic nanoparticles for potential application in simultaneous magnetic targeting and tumor imaging. AAPS J (2009) 0.93
A combined theoretical and in vitro modeling approach for predicting the magnetic capture and retention of magnetic nanoparticles in vivo. J Control Release (2011) 0.92
The artificial peroxidase activity of magnetic iron oxide nanoparticles and its application to glucose detection. Biomaterials (2009) 0.92
Case of complete recovery of pancytopenia after treatment of hypopituitarism. Ann Hematol (2003) 0.91
Cell-penetrating peptides: achievements and challenges in application for cancer treatment. J Biomed Mater Res A (2013) 0.90
Investigation of tyrosine nitration and nitrosylation of angiotensin II and bovine serum albumin with electrospray ionization mass spectrometry. Rapid Commun Mass Spectrom (2007) 0.90
The minimal functional sequence of protamine. Biochem Biophys Res Commun (2005) 0.90
In vitro assessment of a novel polyrotaxane-based drug delivery system integrated with a cell-penetrating peptide. J Control Release (2007) 0.90
The systemic delivery of siRNAs by a cell penetrating peptide, low molecular weight protamine. Biomaterials (2009) 0.90
The magnetophoretic mobility and superparamagnetism of core-shell iron oxide nanoparticles with dual targeting and imaging functionality. Biomaterials (2010) 0.89
Magnetic nanoparticles for tumor imaging and therapy: a so-called theranostic system. Pharm Res (2013) 0.88
PEGylation of bacterial cocaine esterase for protection against protease digestion and immunogenicity. J Control Release (2009) 0.88
Cell-penetrating chitosan/doxorubicin/TAT conjugates for efficient cancer therapy. Int J Cancer (2011) 0.87
Injectable microparticle-gel system for prolonged and localized lidocaine release. I. In vitro characterization. J Biomed Mater Res A (2004) 0.87
PTD-modified ATTEMPTS system for enhanced asparaginase therapy: a proof-of-concept investigation. J Control Release (2008) 0.87
Analysis of the impurities in the methamphetamine synthesized by three different methods from ephedrine and pseudoephedrine. Forensic Sci Int (2006) 0.86
Sensitive high performance liquid chromatographic assay for assessment of doxorubicin pharmacokinetics in mouse plasma and tissues. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 0.86
Co-administration of protein drugs with gold nanoparticles to enable percutaneous delivery. Biomaterials (2010) 0.85
The ATTEMPTS delivery systems for macromolecular drugs. Expert Opin Drug Deliv (2008) 0.85
Bronchial washing yield before and after forceps biopsy in patients with endoscopically visible lung cancers. Respirology (2007) 0.84
Size-tunable synthesis of stable superparamagnetic iron oxide nanoparticles for potential biomedical applications. J Biomed Mater Res A (2010) 0.84
Injectable microparticle-gel system for prolonged and localized lidocaine release. II. In vivo anesthetic effects. J Biomed Mater Res A (2004) 0.83
Intradiscal injection of simvastatin retards progression of intervertebral disc degeneration induced by stab injury. Arthritis Res Ther (2009) 0.83
Preliminary in vivo evaluation of the protein transduction domain-modified ATTEMPTS approach in enhancing asparaginase therapy. J Biomed Mater Res A (2009) 0.83
Transcellular Transport of Heparin-coated Magnetic Iron Oxide Nanoparticles (Hep-MION) Under the Influence of an Applied Magnetic Field. Pharmaceutics (2010) 0.82
Comparison study of the extraction methods of paraquat in post-mortem human blood samples. Arch Pharm Res (2007) 0.82
Tumor vasculature targeting following co-delivery of heparin-taurocholate conjugate and suberoylanilide hydroxamic acid using cationic nanolipoplex. Biomaterials (2012) 0.82
Chemically surface modified gel (CSMG): an excellent enzyme-immobilization matrix for industrial processes. J Biotechnol (2006) 0.82
Multifunctional drug delivery system for targeting tumor and its acidic microenvironment. J Control Release (2012) 0.82
The use of low molecular weight protamine chemical chimera to enhance monomeric insulin intestinal absorption. Biomaterials (2013) 0.81
Drosophila melanogaster model for Mycobacterium abscessus infection. Microbes Infect (2013) 0.81
Cell permeable cocaine esterases constructed by chemical conjugation and genetic recombination. Mol Pharm (2012) 0.81
Chemically and biologically synthesized CPP-modified gelonin for enhanced anti-tumor activity. J Control Release (2013) 0.81
Specific down regulation of 3T3-L1 adipocyte differentiation by cell-permeable antisense HIF1alpha-oligonucleotide. J Control Release (2010) 0.81
Magnetic nanoparticles for MRI of brain tumors. Curr Pharm Biotechnol (2012) 0.81
Polysorbate cationic synthetic vesicle for gene delivery. J Biomed Mater Res A (2011) 0.81
Magnetic targeting of novel heparinized iron oxide nanoparticles evaluated in a 9L-glioma mouse model. Pharm Res (2013) 0.81
Poly(glutamic acid) poly(ethylene glycol) hydrogels prepared by photoinduced polymerization: Synthesis, characterization, and preliminary release studies of protein drugs. J Biomed Mater Res (2002) 0.81
ATTEMPTS system: a macromolecular prodrug strategy for cancer drug delivery. Curr Pharm Des (2010) 0.80
Rapid increase in endothelial nitric oxide production by bradykinin is mediated by protein kinase A signaling pathway. Biochem Biophys Res Commun (2003) 0.80
Orally active desulfated low molecular weight heparin and deoxycholic acid conjugate, 6ODS-LHbD, suppresses neovascularization and bone destruction in arthritis. J Control Release (2012) 0.80
Transcutaneous antigen delivery system. BMB Rep (2013) 0.80
PEG-modified protamine with improved pharmacological/pharmaceutical properties as a potential protamine substitute: synthesis and in vitro evaluation. Bioconjug Chem (2005) 0.79
In vivo delivery of cell-permeable antisense hypoxia-inducible factor 1α oligonucleotide to adipose tissue reduces adiposity in obese mice. J Control Release (2012) 0.79